Adverum Biotechnologies advances wet AMD treatment with promising trial results. See why ADVM stock has potential as it ...

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

Macular degeneration usually refers to the age-related degenerative changes in the retina that can result in loss of central vision. It is caused by abnormal blood vessel growth (a condition ...

Bronte Capital, an investment management company, released its “Amalthea Fund” third-quarter 2024 investor letter. A copy of ...

Based on the scientific progress achieved in the past few years, it is possible that patients with myopic macular degeneration complicated by CNV may benefit from a new ophthalmic frontier of ...

Many people who have age-related macular degeneration don't know it. But ignoring this condition can lead to vision loss that can make it hard to perform everyday tasks. Many people who have ...

Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting ...

Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patien ...

SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Active clinical trial sites now ...

D Molecular Therapeutics, Inc. ( (FDMT) ) has released its Q3 earnings. Here is a breakdown of the information 4D Molecular Therapeutics, Inc.

Opthea (ASX:OPT) has announced a boost to its cash reserves, receiving a $15.9m research and development tax incentive from ...